奧維德治療公司
DE ˙ DB ˙ US6904691010
€2.02 ↑0.02 (1.00%)
2026-06-04
分享價格
SecurityDE:1OT / Ovid Therapeutics Inc.
InstitutionVanguard Group Inc
Latest Disclosed Ownership2,581,736 shares
Ownership 3.66%
Vanguard Group Inc ownership in 1OT / Ovid Therapeutics Inc.

2023-02-09 - Vanguard Group Inc has filed an SC 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 2,581,736 shares of Ovid Therapeutics Inc. (DE:1OT). This represents 3.66 percent ownership of the company. In their previous filing dated 2022-02-10 , Vanguard Group Inc had reported owning 3,442,618 shares, indicating a decrease of -25.01 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date		Effective
Date		Form Prev
Shares		 Latest
Shares		 ΔShares
(Percent)		 Ownership
(Percent)		 ΔOwnership
(Percent)
2023-02-09 2023-02-09 13G/A 3,442,618 2,581,736 -25.01 3.66 -27.67
2022-02-10 2022-02-10 13G 3,442,618 5.06

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-01-29 2025-12-31 13F OVID THERAPEUTICS COM 690469101 3,072,227 251,414 8.91 5,008 36.54 0.0001
2025-11-07 2025-09-30 13F OVID THERAPEUTICS COM 690469101 2,820,813 184,698 7.01 3,667 321.98 0.0001
2025-08-11 2025-06-30 13F OVID THERAPEUTICS COM 690469101 2,636,115 -472,666 -15.20 870 -10.32 0.0000
2025-05-09 2025-03-31 13F OVID THERAPEUTICS COM 690469101 3,108,781 -39,301 -1.25 970 -67.04 0.0000
2025-02-11 2024-12-31 13F OVID THERAPEUTICS COM 690469101 3,148,082 5,643 0.18 2,940 -20.71 0.0001
2024-11-13 2024-09-30 13F OVID THERAPEUTICS COM 690469101 3,142,439 53,046 1.72 3,708 56.06 0.0001
2024-08-13 2024-06-30 13F OVID THERAPEUTICS COM 690469101 3,089,393 113,085 3.80 2,376 -73.82 0.0000
2024-05-10 2024-03-31 13F OVID THERAPEUTICS COM 690469101 2,976,308 -13,469 -0.45 9,078 -5.71 0.0002
2024-03-11 2023-12-31 13F/A-1 OVID THERAPEUTICS COM 690469101 2,989,777 23,360 0.79 9,627 -15.49 0.0002
2024-02-14 2023-12-31 13F OVID THERAPEUTICS COM 690469101 2,989,777 23,360 9,627 0.0002
2023-12-18 2023-09-30 13F/A-1 OVID THERAPEUTICS COM 690469101 2,966,417 67,189 2.32 11,391 19.79 0.0003
2023-11-14 2023-09-30 13F OVID THERAPEUTICS COM 690469101 2,966,417 67,189 11,391 0.0001
2023-08-14 2023-06-30 13F OVID THERAPEUTICS COM 690469101 2,899,228 288,626 11.06 9,509 41.19 0.0002
2023-07-14 2023-03-31 13F/A-1 OVID THERAPEUTICS COM 690469101 2,610,602 28,866 1.12 6,735 40.25 0.0002
2023-05-15 2023-03-31 13F OVID THERAPEUTICS COM 690469101 2,610,602 28,866 6,735 0.0002
2023-02-10 2022-12-31 13F OVID THERAPEUTICS COM 690469101 2,581,736 1,146 0.04 4,802 1.14 0.0001
2022-11-14 2022-09-30 13F OVID THERAPEUTICS COM 690469101 2,580,590 45,500 1.79 4,748 -12.88 0.0001
2022-08-12 2022-06-30 13F OVID THERAPEUTICS COM 690469101 2,535,090 -1,152,819 -31.26 5,450 -52.94 0.0002
2022-05-13 2022-03-31 13F OVID THERAPEUTICS COM 690469101 3,687,909 245,291 7.13 11,580 4.79 0.0003
2022-02-14 2021-12-31 13F OVID THERAPEUTICS COM 690469101 3,442,618 60,537 1.79 11,051 -2.75 0.0003
2021-11-12 2021-09-30 13F OVID THERAPEUTICS COM 690469101 3,382,081 -123,556 -3.52 11,364 -17.09 0.0003
2021-08-13 2021-06-30 13F OVID THERAPEUTICS COM 690469101 3,505,637 9,251 0.26 13,706 -2.49 0.0003
2021-05-14 2021-03-31 13F OVID THERAPEUTICS COM 690469101 3,496,386 390,634 12.58 14,056 95.93 0.0004
2021-02-12 2020-12-31 13F OVID THERAPEUTICS COM 690469101 3,105,752 509,417 19.62 7,174 -51.86 0.0002
2020-11-16 2020-09-30 13F OVID THERAPEUTICS COM 690469101 2,596,335 474,703 22.37 14,903 -4.69 0.0005
2020-08-14 2020-06-30 13F OVID THERAPEUTICS COM 690469101 2,121,632 422,661 24.88 15,636 208.77 0.0006
2020-05-15 2020-03-31 13F OVID THERAPEUTICS COM 690469101 1,698,971 210,442 14.14 5,064 -18.02 0.0002
2020-02-14 2019-12-31 13F OVID THERAPEUTICS COM 690469101 1,488,529 423,961 39.82 6,177 79.10 0.0002
2019-11-14 2019-09-30 13F OVID THERAPEUTICS COM 690469101 1,064,568 -33,046 -3.01 3,449 69.90 0.0001
2019-08-14 2019-06-30 13F OVID THERAPEUTICS COM 690469101 1,097,614 443,490 67.80 2,030 75.30 0.0001
2019-05-15 2019-03-31 13F OVID THERAPEUTICS COM 690469101 654,124 361,864 123.82 1,158 63.56 0.0000
2019-02-14 2018-12-31 13F OVID THERAPEUTICS COM 690469101 292,260 -154,510 -34.58 708 -72.05 0.0000
2018-12-13 2018-09-30 13F/A-2 OVID THERAPEUTICS COM 690469101 446,770 2,003 0.45 2,533 -26.98 0.0001
2018-11-23 2018-09-30 13F/A-1 OVID THERAPEUTICS COM 690469101 446,770 0 2,533 0.0001
2018-11-14 2018-09-30 13F OVID THERAPEUTICS COM 690469101 446,770 2,003 2,533
2018-08-14 2018-06-30 13F OVID THERAPEUTICS COM 690469101 444,767 44,237 11.04 3,469 22.49 0.0001
2018-05-15 2018-03-31 13F OVID THERAPEUTICS COM 690469101 400,530 66,464 19.90 2,832 -14.13 0.0001
2018-02-14 2017-12-31 13F OVID THERAPEUTICS COM 690469101 334,066 172,409 106.65 3,298 138.12 0.0001
2017-11-14 2017-09-30 13F OVID THERAPEUTICS COM 690469101 161,657 62,340 62.77 1,385 32.92 0.0001
2017-08-24 2017-06-30 13F/A-1 OVID THERAPEUTICS COM 690469101 99,317 99,317 1,042 0.0001
2017-08-11 2017-06-30 13F OVID THERAPEUTICS COM 690469101 99,317 1,042 0.0001
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.